OWCP - OWC Pharmaceutical Research Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.45
-0.02 (-4.26%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.47
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume1,372,453
Market Cap65.843M
Beta-11.79
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire3 months ago

    OWC Pharma Issues Chairman's Letter to Shareholders

    OWC Pharma (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a letter to shareholders. Following my recent appointment as Chairman at OWC Pharma (OWCP), it is my pleasure to introduce myself to you and to initiate a new tradition of biannual shareholder update letters.

  • PR Newswire5 months ago

    OWC Pharmaceutical Research Corp Appoints Dr. Stanley Hirsch as its Active Chairman

    OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Stanley Hirsch as its active chairman of the board of directors. Dr. Stanley Hirsch, age 59, has had extensive scientific, executive and board level experience for more than the past 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M&A activity together with multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States.

  • Marketwired5 months ago

    CFN Media Exclusive Interview with OWCP's Dr. Sharon Rozenblat

    CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article and exclusive interview with Dr. Sharon Rozenblat, Advisory Board ...

  • PR Newswire5 months ago

    OWC Pharmaceutical Research Takes Further Actions to Protect its Intellectual Property

    OWC Pharmaceutical Research Corp. (OWCP) today announced that its wholly-owned, Israel-based subsidiary, One World Cannabis Ltd. (OWC), has filed a patent application with the European Union Patent and Trademark Office for its active cannabinoid-based psoriasis topical cream.

  • PR Newswire6 months ago

    OWC Pharmaceutical Research Corp. Announces Market Readiness of its Cannabinoid-based Topical Cream for Skin Conditions Starting With Psoriasis

    OWC Pharmaceutical Research Corp. (OWCP) today announced that its wholly-owned, Israel-based subsidiary, One World Cannabis Ltd. (OWC), has filed a patent application with the United States Patent and Trademark Office for its active cannabinoid-based topical cream. This new patent application follows the previously filed 'provisional' patent application.

  • Marketwired6 months ago

    OWC Pharmaceuticals Engages CFN Media to Cultivate New Investor Audience & Communicate with Existing Shareholders

    CFN Media Group , the leading agency and digital media network dedicated to the North American cannabis industry, today announced that OWC Pharmaceutical Research Corp. has engaged CFN Media to conduct ...

  • PR Newswire7 months ago

    OWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts

    OWC Pharmaceutical Research Corp. (OWCP) and mediq Innovation Partners (mediq) are pleased to announce an agreement for the introduction of OWCP's active cannabinoid-based topical psoriasis cream to the German market. Frankfurt, Germany-based mediq has extensive experience, knowledge and a successful track record in enabling Israel-based companies to penetrate the European markets.

  • PR Newswire7 months ago

    OWC Pharmaceutical Research Announces Update on Multiple Myeloma Study

    OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that the Scientific Advisory Team of its wholly owned Israeli subsidiary, One World Cannabis Ltd. ("OWC") has determined the road map for continuing the Multiple Myeloma study.

  • PR Newswire8 months ago

    OWC Pharmaceutical Research Corp. to Present at Monaco Growth Forums in Monaco

    PETACH TIKVA, Israel, April 17, 2017 /PRNewswire/ -- The Monaco Growth Forums by Andreea Porcelli and OWC Pharmaceutical Research Corp. (OTC: OWCP), are pleased to announce that OWCP  has been invited ...

  • PR Newswire8 months ago

    OWC Pharmaceutical Research Corp. Announces World-Wide Expression of Interest in its Cannabis-based Topical Cream for Treatment of Psoriasis and other Skin Disorders

    OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it has received expressions of interest from the scientific and medical communities world-wide as a result of its recently announce positive preliminary clinical efficacy tests results of its topical cream to treat Psoriasis. OWCP's scientific team, led by the renowned Dr. Yehuda Baruch, the Company's Chief Science Officer and OWC's Director of Research and Regulatory Affairs, and former Director of Israel's Ministry of Health Medical Management Division, previously reported trial results and concluded that post-application of OWC's unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis.

  • PR Newswire9 months ago

    OWC Pharmaceutical Research Corp Releases Promising Preliminary Results From Efficacy Tests of its Topical Cream

    OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of medical conditions and disorders, today announced the highly promising results of its topical cream efficacy tests following months of study and scientific analysis. In October 2016, OWC announced that it was in the final phase of pre-clinical efficacy testing for its topical psoriasis cream and also announced a parallel test to assess the efficacy of the formulation in treating psoriasis in human skin tissue.

  • Marketwired10 months ago

    CFN Media Exclusive Interview with OWCP CSO Dr. Yehuda Baruch

    CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article and exclusive interview with Dr. Yehuda Baruch, Chief Science ...

  • Accesswire10 months ago

    Traders News Issues Comprehensive Report on OWC Pharmaceutical Research Corp

    NEW YORK, NY / ACCESSWIRE / February 27, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies is issuing a comprehensive ...

  • PR Newswire10 months ago

    OWC Pharmaceutical Research Corp Receives IRB Approval to Initiate Safety Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis

    OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it has received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical crème compound for the treatment of psoriasis and related skin conditions. The approval follows the Company's February 1, 2017 8K filing announcing an extension to the size and scope of its efficacy study on the same compound, which began in November 2106.

  • PR Newswire10 months ago

    OWC Pharmaceutical Research to Present at Lyons Capital’s Wall Street Conference

    OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that it will be presenting at the Wall Street Conference. The event will be held at the Hilton Doubletree Hotel and Conference Center in Deerfield Beach/ Boca Raton, Florida, on Wednesday, March 1, 2017. The Wall Street Conference is the premiere conference in the venture capital arena and small-cap marketplace.

  • PR Newswire10 months ago

    OWC Pharmaceutical Research Corp Appoints Dr. Sharon Rozenblat Senior Advisor to Scientific Advisory Board of its Wholly-Owned Subsidiary

    OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Sharon Rozenblat as Senior Advisor to the Scientific Advisory Board of its wholly-owned Israeli subsidiary, One World Cannabis Ltd ("OWC Israel"). Dr. Rozenblat will be tasked with overseeing the completion of the pre-clinical safety studies on the Company's treatment for psoriasis, which commenced in November 2016.

  • PR Newswire11 months ago

    OWC Pharmaceutical Research Corp Announces the Nominations of Ms. Miriam Sani, MSc Eng., to its Advisory Board

    OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of medical conditions and disorders, today announced that Ms. Miri Sani has accepted nomination to the Company's Advisory Board. Ms. Sani, who received an MSc [Master of Science Degree) in Chemistry from the Technion - Israel Institute of Technology, Haifa, Israel, will advise OWC's management on the transition of its innovatively-developed cannabinoid products and delivery systems developed internally and through its hospital relationships, to full industrial and commercial production, in strict compliance with all local and state regulations and protocols, working closely with applicable healthcare agencies and ministries.

  • PR Newswire11 months ago

    OWC Pharmaceutical Research Corp Issues Annual Letter to Shareholders

    OWC Pharmaceutical Research Corp. (OWCP), ("OWCP" or the "Company"), through its Israeli based fully owned subsidiary (One world Cannabis Ltd ) , a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today released its annual letter to the Company's shareholders. OWC Pharmaceutical Research Corporation (OWCP) is pleased to provide you with an update on the progress we made during 2016.

  • Marketwired11 months ago

    CFN Media Exclusive Interview with Jeffrey Friedland, Advisory Board Member for OWC Pharmaceutical Research

    CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an exclusive interview with Jeffrey Friedland, CEO of Intiva Inc. and member ...